Abstracts tagged "interferons"

Abstract Number: 844 • 2012 ACR/ARHP Annual Meeting
Toll-Like Receptor 9-Independent and Immune Complex-Independent Interferon-α Production by Neutrophils Upon Netosis in Response to Circulating Chromatin
Dennis Lindau¹, Julie Mussard², Armin Rabsteyn¹, Matthieu Ribon², Ina Kötter³, Annette Igney³, Gosse Adema⁴, Marie-Christophe Boissier⁵, Hans-Georg Rammensee¹ and Patrice Decker⁶, ¹Department of Immunology, University of Tübingen, Institute for Cell Biology, Tübingen, Germany, ²INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ³Department of Internal Medicine II, Rheumatology Division, Tübingen, Germany, ⁴Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands, ⁵Avicenne Hospital, Rheumatology Department, Bobigny, France, ⁶EA4222, Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France
Background/Purpose: Chromatin (which is composed of DNA and histones) represents a major autoantigen in systemic lupus erythematosus (SLE). Interferon-α (IFN-α) plays an important role in…
Abstract Number: 740 • 2012 ACR/ARHP Annual Meeting
Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification
Melissa E. Munroe¹, Jourdan R. Anderson², Julie M. Robertson³, Timothy B. Niewold⁴, George C. Tsokos⁵, Michael P. Keith⁶, John B. Harley⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁷Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation; Oklahoma University Health Sciences Center, Oklahoma City, OK
Background/Purpose: The processes that lead to clinical illness in systemic lupus erythematosus (SLE) years before diagnosis are not well characterized. Several cytokines have been associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].